Tenet Healthcare Corporation (THC) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (steady margins, 28% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-02, Tenet Healthcare Corporation (NYSE: THC) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $273.25 (+0.99% 1D, market cap $21.79B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, THC ranks #46 in composite RQD confidence.
Within the Health Care sector (Hospital/Nursing Management), THC carries a Roarable B (74/100 RQD), trailing P/E of 9.2x, gross margin of —, and ROIC of 27.6%. By comparison, EHC (Encompass Health Corporation) holds a B+ grade (77/100 RQD, P/E 22.9x, ROIC 13.8%, cap $12.97B) and ENSG (The Ensign Group Inc.) posts a B grade (72/100 RQD, P/E 31.6x, ROIC 18.0%, cap $10.87B). Among the 5-stock peer group, UHS leads on earnings multiple (7.0x) while THC leads on capital efficiency (27.6% ROIC).
Per THC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000070318), Tenet Healthcare Corporation generated $21.31B in revenue (+3.1% YoY), $2.37B in net income, and $2.53B in free cash flow against $29.68B in total assets and $9.32B in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±6.1% realized swing band)
SEC XBRL FY 2025 (10-K): 11.9% FCF Margin ($2.53B FCF) & 52% Gross Margin
Balance-sheet & 10-K footnote risk deducts 10 pts from forensic ceiling
Even with a 74/100 (B) score, THC faces multiple-compression risk if 9.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($264.51) or 200D SMA ($220.92) invalidates the momentum regime and cuts Target Base ($292.92) toward Bear Floor ($224.06).
Tenet Healthcare Corporation (THC) advanced +0.99% to $273.25, trading at 92% of its 52-week range ($157.58 – $283.05). High-quality cash engine (steady margins, 28% return on capital) with steady institutional support.
Yahoo! Finance Canada report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
LifeStance Stock is flirting with its latest buy point amid the ongoing stock market weakness. Its RS line hit a new high last week.
Wells Fargo analyst Stephen Baxter maintains Tenet Healthcare (NYSE:THC) with a Overweight and raises the price target from $281 to $321.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +3.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on THC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for THC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Tenet Healthcare Corporation (THC) ranks #46 by composite RQD confidence (74/100, grade B) and #71 by equity capitalization ($21.79B). Within this direct 5-issuer industry benchmark cohort, UHS leads on earnings valuation at 7.0x trailing P/E, while THC leads on capital efficiency and profitability with 27.6% ROIC and — gross margin. EHC currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with THC at 74/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| THC
ACTIVE
Tenet Healthcare Corporation | B | 74/100 | 9.2x | — | 27.6% | +0.99% | $21.79B | Benchmark Subject |
| EHC Encompass Health Corporation | B+ | 77/100 | 22.9x | — | 13.8% | +3.35% | $12.97B | /ehc-vs-thc → |
| ENSG The Ensign Group Inc. | B | 72/100 | 31.6x | 20.1% | 18.0% | -2.58% | $10.87B | /ensg-vs-thc → |
| UHS Universal Health Services Inc. | C | 63/100 | 7.0x | — | 14.1% | -0.32% | $10.41B | /uhs-vs-thc → |
| PACS PACS Group Inc. | B | 74/100 | 41.1x | — | 24.6% | -3.76% | $7.87B | /pacs-vs-thc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tenet Healthcare Corporation (THC) reported GAAP revenue of $21.31B (+3.1% vs. FY2024 revenue of $20.68B , and +3.6% cumulative change since FY2023) , GAAP net income of $2.37B, operating cash flow of $3.54B, and free cash flow of $2.53B (+126.7% YoY). On the balance sheet, THC closed FY2025 with $29.68B in total assets against $9.32B in total debt (Altman Z-Score: 2.08, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $21.31B | $2.37B | $3.54B | $2.53B | $29.68B | $9.32B |
| FY2024 (FY) | 2024-12-31 | $20.68B | $4.06B | $2.05B | $1.12B | $28.94B | $9.18B |
| FY2023 (FY) | 2023-12-31 | $20.56B | $1.31B | $2.37B | $1.45B | $24.68B | $5.77B |
As of 2026-11-02, Tenet Healthcare Corporation (NYSE: THC) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $273.25 (+0.99% 1D, market cap $21.79B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, THC ranks #46 in composite RQD confidence.
Within the Health Care sector (Hospital/Nursing Management), THC carries a Roarable B (74/100 RQD), trailing P/E of 9.2x, gross margin of —, and ROIC of 27.6%. By comparison, EHC (Encompass Health Corporation) holds a B+ grade (77/100 RQD, P/E 22.9x, ROIC 13.8%, cap $12.97B) and ENSG (The Ensign Group Inc.) posts a B grade (72/100 RQD, P/E 31.6x, ROIC 18.0%, cap $10.87B). Among the 5-stock peer group, UHS leads on earnings multiple (7.0x) while THC leads on capital efficiency (27.6% ROIC).
Per THC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000070318), Tenet Healthcare Corporation generated $21.31B in revenue (+3.1% YoY), $2.37B in net income, and $2.53B in free cash flow against $29.68B in total assets and $9.32B in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.
THC last traded at $273.25 (+0.99% on volume of 1,209,626 shares), positioning the stock +3.30% above its 50-day simple moving average ($264.51) and +23.69% above its 200-day simple moving average ($220.92). Across its 52-week range of $157.58 to $283.05, THC sits at the 92.2% percentile with a 14-day RSI of 54.8 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($256.58 to $289.92).
Why THC Stock advanced +0.99% Today — RQD Quant Desk Flash. High-quality cash engine (steady margins, 28% return on capital) with steady institutional support.
Per the Roarable RQD rating, THC scores 74 out of 100 (letter grade B; verdict label "Roarable Buy — Good Risk/Reward"). The five pillars break down as follows:
Taken together, an investor should read the rating as a case built on strong cash generation and institutional support, offset by leverage and moderate macro sensitivity. The valuation inputs (P/E TTM of 9.2, Forward P/E of 8.6) appear on the market data side and reflect the price relative to earnings, but the rating itself does not state a fair-value estimate.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $21310.0M | $3508.0M | $2367.0M | N/A | $2530.0M | $2883.0M | $9316.8M |
| FY 2024 | $20675.0M | $5956.0M | $4064.0M | N/A | $1116.0M | $3019.0M | $9175.0M |
| FY 2023 | $20564.0M | $2510.0M | $1311.0M | N/A | $1448.6M | N/A | $5774.4M |
Per the SEC financials, revenue was broadly flat across the three periods, while net income and operating income moved more variably, with FY 2024 showing the highest operating income and net income of the periods shown. Per the market data, operating margin is 16.5% and net margin is 11.1%. The Altman Z-Score (2.08) and Piotroski F-Score (6/9) are cited in the RQD rating, and the RQD rating references Debt/Equity of 2.06, indicating a leveraged balance sheet. Per the SEC financials, reported debt increased from $5774.4M in FY 2023 to $9316.8M in FY 2025.
Per the recent news and catalysts section, six items were reported, all tagged to THC:
Risk watch items: the source summaries are generic and do not state specific risks. Per the Butterfly Supply-Chain Graph, no proprietary signals are present. The news summaries do not provide substantive detail beyond the headlines and general descriptions.
Real-time company headlines, analyst actions, and sector developments for Tenet Healthcare Corporation (THC) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
www.debelegger.nl report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Tenet Healthcare Corporation (THC) market action, institutional positioning, and fundamental catalysts.
Welcome to the THC (Tenet Healthcare Corporation) Roar Pit. Current RQD Composite is 74/100 (Roarable Buy — Good Risk/Reward) in Hospital/Nursing Management. Bulls point to capital efficiency (27.6% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on THC, but look at what you are paying: 9.2x trailing P/E with tightening sector spreads. Unless Tenet Healthcare Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on THC, the market is fixating on short-term headline noise in Hospital/Nursing Management and ignoring the balance sheet and cash flow trajectory. At $270.57 (52-wk range $157.58 - $283.05), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).